74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Insmed
Closed
SectorHealthcare
68.84 -2.71
Overview
Share price change
24h
Min
66.3
Max
70.87
Income | -15M -236M |
|---|---|
Sales | 11M 104M |
EPS | -1.32 |
Profit margin | -225.53 |
Employees | 1,271 |
EBITDA | -47M -244M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +38.21% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 2.2B 14B |
|---|---|
Previous open | 71.55 |
Previous close | 68.84 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Insmed Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Insmed Forecast
Price Target
By TipRanks
38.21% upside
12 Months Forecast
Average 97.85 USD 38.21%
High 110 USD
Low 90 USD
Based on 15 Wall Street analysts offering 12 month price targets forInsmed - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
